Health care stocks were edging lower Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing about 0.1%.
The iShares Biotechnology ETF (IBB) climbed 1.9%.
In corporate news, UnitedHealth Group's (UNH) Medicare billing practices are under investigation by the US Justice Department's criminal healthcare-fraud unit, The Wall Street Journal reported. UnitedHealth shares fell 1.6%.
Merck (MRK) agreed to buy UK-based Verona Pharma (VRNA) in a deal worth $10 billion to expand its cardio-pulmonary disease treatment portfolio. Merck shares rose 3.2%, and Verona jumped past 20%.
CVS Health's (CVS) Omnicare unit was ordered to pay $948.8 million in penalties and damages in a whistleblower lawsuit alleging it fraudulently billed the US government for invalid drug prescriptions, Reuters reported, citing a court order. CVS shares were down 0.5%.
Rhythm Pharmaceuticals (RYTM) shares jumped 35% after the company said bivamelagon achieved body mass index reductions in patients in a phase 2 acquired hypothalamic obesity trial.
Comments